[go: up one dir, main page]

WO2015185998A3 - Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse - Google Patents

Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse Download PDF

Info

Publication number
WO2015185998A3
WO2015185998A3 PCT/IB2015/001425 IB2015001425W WO2015185998A3 WO 2015185998 A3 WO2015185998 A3 WO 2015185998A3 IB 2015001425 W IB2015001425 W IB 2015001425W WO 2015185998 A3 WO2015185998 A3 WO 2015185998A3
Authority
WO
WIPO (PCT)
Prior art keywords
sdf
signaling pathway
kinase
bone marrow
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/001425
Other languages
English (en)
Other versions
WO2015185998A2 (fr
Inventor
Raquel IZUMI
Francisco SALVA
Ahmed HAMDY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acerta Pharma BV
Original Assignee
Acerta Pharma BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma BV filed Critical Acerta Pharma BV
Publication of WO2015185998A2 publication Critical patent/WO2015185998A2/fr
Publication of WO2015185998A3 publication Critical patent/WO2015185998A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dans certains modes de réalisation, cette invention concerne de nouveaux inhibiteurs à petites molécules qui bloquent la voie de signalisation des CXCR4-SDF-1 par inhibition directe des membres de la famille des kinases Tec, à savoir la kinase X de moelle osseuse (BMX) (également connue sous le nom de tyrosine kinase épithéliale et endothéliale (ETK)), et leur utilisation pour traiter les maladies chez lesquelles la pathogenèse est médiée par la voie de signalisation des CXCR4-SDF-1.
PCT/IB2015/001425 2014-04-11 2015-04-10 Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse Ceased WO2015185998A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978760P 2014-04-11 2014-04-11
US61/978,760 2014-04-11

Publications (2)

Publication Number Publication Date
WO2015185998A2 WO2015185998A2 (fr) 2015-12-10
WO2015185998A3 true WO2015185998A3 (fr) 2016-04-07

Family

ID=54337820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/001425 Ceased WO2015185998A2 (fr) 2014-04-11 2015-04-10 Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse

Country Status (1)

Country Link
WO (1) WO2015185998A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10899767B2 (en) 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039218A2 (fr) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
WO2013010868A1 (fr) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
WO2013059738A2 (fr) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2013081016A1 (fr) * 2011-11-29 2013-06-06 小野薬品工業株式会社 Chlorhydrate de dérivé de purinone
WO2014025976A1 (fr) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2014068527A1 (fr) * 2012-11-02 2014-05-08 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton
WO2015181633A2 (fr) * 2014-04-11 2015-12-03 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation cxcr4/sdf-1 à l'aide d'inhibiteurs de la tyrosine kinase de bruton

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO2003009817A2 (fr) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
WO2005014599A1 (fr) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines et methodes d'inhibition de la tyrosine kinase de bruton par de tels composes
WO2005005429A1 (fr) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
AR046337A1 (es) 2003-10-15 2005-12-07 Osi Pharm Inc Imidazopirazina inhibidoras de las tirosinquinasas
WO2007147001A2 (fr) 2006-06-14 2007-12-21 Imclone Systems Incorporated Formulations lyophilisées d'anticorps anti-egfr
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
WO2009088986A1 (fr) 2008-01-04 2009-07-16 Intellikine, Inc. Entités chimiques, compositions et procédés
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
WO2012021444A1 (fr) 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Sel de bésylate d'un inhibiteur de btk
CA2760174A1 (fr) 2011-12-01 2013-06-01 Pharmascience Inc. Inhibiteurs de proteines kinases et leurs utilisations
PH12013501922A1 (en) 2011-04-04 2013-11-25 Pharmascience Inc Protein kinase inhibitors
EP2710007B1 (fr) 2011-05-17 2019-12-11 The Regents of The University of California Inhibiteurs de kinase
EP2734523A1 (fr) 2011-07-19 2014-05-28 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
RS55770B1 (sr) 2013-04-25 2017-07-31 Beigene Ltd Fuzionisana heterociklična jedinjenja kao inhibitori protein kinaze
US20150005277A1 (en) 2013-06-28 2015-01-01 Beigene, Ltd. Protein Kinase Inhibitors and Uses Thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039218A2 (fr) * 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
WO2013010868A1 (fr) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
WO2013059738A2 (fr) * 2011-10-19 2013-04-25 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2013081016A1 (fr) * 2011-11-29 2013-06-06 小野薬品工業株式会社 Chlorhydrate de dérivé de purinone
EP2786996A1 (fr) * 2011-11-29 2014-10-08 ONO Pharmaceutical Co., Ltd. Chlorhydrate de dérivé de purinone
WO2014025976A1 (fr) * 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Composés hétéroromatiques en tant qu'inhibiteurs de la tyrosine kinase de bruton (btk)
WO2014068527A1 (fr) * 2012-11-02 2014-05-08 Pfizer Inc. Inhibiteurs de la tyrosine kinase de bruton
WO2015181633A2 (fr) * 2014-04-11 2015-12-03 Acerta Pharma B.V. Procédés de blocage de la voie de signalisation cxcr4/sdf-1 à l'aide d'inhibiteurs de la tyrosine kinase de bruton

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FEIYANG LIU ET AL: "Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer", ACS CHEMICAL BIOLOGY, vol. 8, no. 7, 19 July 2013 (2013-07-19), pages 1423 - 1428, XP055099883, ISSN: 1554-8929, DOI: 10.1021/cb4000629 *
JARBOE JOHN S ET AL: "Mini-Review: Bmx Kinase Inhibitors for Cancer Therapy", RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, BENTHAM SCIENCE PUBLISHERS LTD, GB, vol. 8, no. 3, 1 September 2013 (2013-09-01), pages 228 - 238, XP009175944, ISSN: 1574-8928 *
TAI YU-TZU ET AL: "Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.", BLOOD 30 AUG 2012, vol. 120, no. 9, 30 August 2012 (2012-08-30), pages 1877 - 1887, XP002753052, ISSN: 1528-0020 *
ZAITSEVA LYUBOV ET AL: "Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML", ONCOTARGET, IMPACT JOURNALS LLC, UNITED STATES, vol. 5, no. 20, 30 October 2014 (2014-10-30), pages 9930 - 9938, XP009188002, ISSN: 1949-2553 *

Also Published As

Publication number Publication date
WO2015185998A2 (fr) 2015-12-10

Similar Documents

Publication Publication Date Title
ZA202401324B (en) Tyrosine kinase inhibitors
WO2015181633A3 (fr) Procédés de blocage de la voie de signalisation cxcr4/sdf-1 à l'aide d'inhibiteurs de la tyrosine kinase de bruton
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
IL281805A (en) Quinazoline derivatives as tyrosine kinase inhibitors, preparations, methods for their preparation and use
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
MX383140B (es) Heterociclos bicíclicos como inhibidores de receptor del factor de crecimiento de fibroblastos (fgfr4).
CL2012003048A1 (es) Compuestos derivados de n-fenil-3-(1h-pirazol-4-il)quinoxalin-6-amina, inhibidores de tirosino quinasa fgfr; proceso de preparación; composición farmacéutica; y su uso en la prevención o tratamiento de cáncer.
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
EA201792047A1 (ru) Новые соединения
EA201592005A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EP4338802A3 (fr) Inhibiteurs de tyk2, utilisations et procédés de production associés
MX2018001395A (es) Derivados de pirazol pirimidina y sus usos.
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201691472A1 (ru) Конденсированные пиримидины в качестве ингибиторов комплекса p97
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
PH12018501646A1 (en) Compositions and methods for treating infections
MX2017014752A (es) Nuevos etinos de amidoheteroaril aroil hidrazida.
WO2015185998A3 (fr) Procédés de blocage de la voie de signalisation des cxcr-4/sdf-1 à l'aide d'inhibiteurs de kinase x de moelle osseuse
FR3018045B1 (fr) Composition ophtalmique remanente, notamment pour le traitement de la secheresse oculaire
CL2016003102A1 (es) 1h-1,8-naftiridin-2-onas como compuestos antiproliferativos.
EA202191318A1 (ru) Ингибиторы тирозинкиназы, составы и способы их применения

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15784147

Country of ref document: EP

Kind code of ref document: A2